Ambros Therapeutics will take the Nasdaq spot of Werewolf Therapeutics, a cancer biotech that has been exploring strategic alternatives for most of this year, the companies said Friday morning.
A California biotech with a chronic pain drug that’s long been approved in Italy, but not the US, is going onto the public markets through …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Caldera-Synlogic and Vidya-Processa ink reverse mergers with Bain-backed placements, advancing a TL1A bispecific and a BTK…
Journavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?
Werewolf Therapeutics and Ambros Therapeutics merge in an all-stock deal with $150M in financing to advance Phase 3 CRPS-1…
Four months after Theravance Biopharma shut down its R&D unit, laid | Four months after Theravance Biopharma shut down its R&D…
Latigo Biotherapeutics published positive data for an acute-pain drug meant to rival a Vertex medicine already on the market
Boundless Bio hands Nasdaq listing to Serapha Bio in reverse merger with $230M in financing; CARsgen wins world's first CAR-T…
